Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy

Figures & data

Table 1 Summary of the published clinical trials and outcome measures for cabozantinib therapy

Study	Description	Patients (n)	Primary end point	OS	Median PFS	ORR
Shojaei et al^Citation18	Phase Ib drug–drug interaction study	25	Safety and tolerability	15.0 months	12.9 months	PR 28%
Choueiri et al^Citation16	Phase III randomized on C vs E	658	PFS	C 21.4 months E 16.5 months	C 7.4 months E 3.8 months	C: PR 21% E: PR 5%

Abbreviations: OS, overall survival; PFS, progression-free survival; ORR, objective response rate; PR, partial response; C, cabozantinib; E, everolimus.

ShojaeiFLeeJHSimmonsBHHGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumorsCancer Res20107024100901010020952508

 PubMed Web of Science ®Google Scholar

ChoueiriTKVaishampayanURosenbergJEPhase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinomaJ Clin Oncol201331218118623213094

 PubMed Web of Science ®Google Scholar